Listen to this post

On February 20, 2025, the ERISA Industry Committee (ERIC) announced that its legal counsel submitted a letter to the U.S. Departments of Labor (DOL), Health and Human Services (HHS) and Treasury, requesting a stay of enforcement of the September 2024 Mental Health Parity and Addiction Equity Act (MHPAEA) Final Rule. In the letter, ERIC urged the Departments to exercise their authority under 5 U.S.C. § 705 to postpone the effective date of the Final Rule while litigation challenging its validity is ongoing. This request marks a significant development in the legal landscape surrounding mental health parity laws and could have far-reaching implications for employers, health plans, and other stakeholders in the health insurance industry.

“Taking action to stay the Mental Health Parity Rule provides needed certainty to all parties as the suit works its way through the judicial process.”

—Tom Christina, Executive Director of the ERIC Legal Center

In January 2025, ERIC filed a complaint in federal court seeking to invalidate the Final Rule, alleging overreach and non-compliance with statutory frameworks. ERIC notably refrained from requesting a temporary restraining order (TRO). A TRO in the context of a rulemaking pauses the implementation of a new rule by preventing an agency from enforcing it until the court can fully review its legality. ERIC’s current request for relief under 5 U.S.C. § 705 signals its ongoing concern about the burdens of the Final Rule and its potential to harm those attempting to comply with the updated MHPAEA requirements.

In its letter, ERIC relies on Section 705 in Title 5 of the U.S. Code, which provides that the Departments “may postpone the effective date of action taken by it, pending judicial review.” ERIC formally requested that the Departments invoke this authority and issue a stay by Tuesday, February 25.

ERIC reiterates the concerns outlined in its complaint and argues that the Final Rule’s new requirements will fundamentally alter the mental health and substance use disorder (MH/SUD) benefits currently offered, while dramatically increasing the costs and complexity of providing such coverage.

The Final Rule took effect on November 22, 2024. However, the Final Rule’s requirements did not apply to group health plans until the first plan year beginning on or after January 1, 2025. Recognizing the challenges of implementing these changes, the Departments further delayed the applicability of certain provisions to January 1, 2026. These delayed provisions include:

  1. The “meaningful benefits” standard;
  2. Prohibitions on discriminatory factors and evidentiary standards;
  3. Data evaluation requirements; and
  4. Related requirements for comparative analyses.

ERIC contends that the requirements of the Final Rule impose significant compliance challenges and costs. Employers and health plans are already planning for the 2026 plan year and must build new systems to collect and store data, reprogram existing systems, reanalyze outcomes, and redesign benefits to meet the Final Rule’s standards. ERIC argues that these costs will continue to mount unless the Departments issue a stay on enforcing the Final Rule.

In the letter, ERIC points to prior instances where federal agencies have invoked 5 U.S.C. § 705 to delay enforcement of controversial rules pending litigation. For example, ERIC cites to an action taking by the DOL during the Obama administration postponing the effective date of its “wage rule” as support. ERIC argues that the same rationale applies here, as a stay would provide necessary relief to impacted entities while the court evaluates the legal merits of the Final Rule.

The implications of a stay on the Final Rule are multifaceted. If the Departments grant ERIC’s request, enforcement of the Final Rule would be temporarily halted, allowing the courts to fully consider the legal arguments and potential impacts before any irreparable injury, loss, or damages take effect. A stay would preserve the court’s ability to provide meaningful relief if the Final Rule if ultimately invalidated. A stay would also provide immediate relief to employers and health plans, particularly small and medium-sized businesses that may lack the resources to swiftly implement the necessary changes. Additionally, it would give all stakeholders additional time to prepare for compliance with the Final Rule’s complex standards and mitigate potential operational disruptions.

ERIC asserts that the stay would balance the interests of all parties by preventing premature enforcement of the Final Rule while ensuring that the litigation process can proceed without causing undue harm. A stay would provide temporary relief from the immediate compliance obligations, allowing more time to adapt to the regulatory changes while the courts deliberate on the Final Rule’s legality. The outcome of the Court’s decision will determine the rules that insurers and employer health plans operate under with respect to MH/SUD benefits.

For questions about this or other behavioral health topics, please contact Natasha Sumner, Taylor Crossley, Noreen Vergara or another member of our Behavioral Health Regulatory team.

Print:
Email this postTweet this postLike this postShare this post on LinkedIn
Photo of Natasha Sumner Natasha Sumner

Natasha co-leads the firms’ Psychedelics and Emerging Therapies Practice Group and is also part of the product liability team. She focuses her practice on assisting clients in navigating the regulatory scheme for conducting clinical trials on psychedelics and other controlled substances and litigating

Natasha co-leads the firms’ Psychedelics and Emerging Therapies Practice Group and is also part of the product liability team. She focuses her practice on assisting clients in navigating the regulatory scheme for conducting clinical trials on psychedelics and other controlled substances and litigating product liability claims.

Natasha is well-versed in historical and current psychedelic research including recent FDA-approved studies on MDMA and psilocybin use for mental health and end-of-life issues, the legalization and decriminalization of psylocibin in numerous cities and states, and biotech and pharmaceutical research. Natasha’s interest in this area keeps her at the forefront of assisting clients in navigating regulatory uncertainty, legislative advocacy, corporate transactions, and ­­­­­­­­­­litigation in this rapidly evolving complex area. Natasha is also dedicated to insuring diversity, equity, and inclusion and recognizing and preserving indigenous knowledge.

Academic institutions, product manufacturers and commercial businesses are among the clients relying on Natasha’s broad experience. Natasha has defended clients against claims of mold, asbestos, and benzene exposure, including landlords and housing authorities in disputes regarding habitability. She has represented clients alleging violations under the Food, Drug, and Cosmetic (FD&C) Act, and counseled clients regarding California’s Proposition 65 warning requirements, among other state and federal laws.

While in law school, Natasha interned with the California Attorney General Energy Task Force, working on antitrust issues related to the state’s 2001 energy crisis. Her inside view of regulatory issues is appreciated by clients as she navigates them through various complex litigation and compliance.

Photo of Taylor Crossley Taylor Crossley

Taylor focuses on healthcare regulatory matters. At Husch Blackwell, she focuses on matters such as healthcare privacy, confidentiality, and mental health law (including 42 C.F.R. Part 2, the Mental Health Parity and Addiction Equity Act, the SUPPORT for Patients & Communities Act, and

Taylor focuses on healthcare regulatory matters. At Husch Blackwell, she focuses on matters such as healthcare privacy, confidentiality, and mental health law (including 42 C.F.R. Part 2, the Mental Health Parity and Addiction Equity Act, the SUPPORT for Patients & Communities Act, and emerging therapy). She also assists with issues relating to healthcare quality, including adverse event reporting, licensure and certification questions, and the Health Care Quality Improvement Act.

Photo of Noreen Vergara Noreen Vergara

As a Healthcare Regulatory Attorney and former executive, Noreen is a transparent communicator and innovative problem solver with a deep background in operations and risk management.

Noreen’s career in healthcare operations, healthcare compliance and executive leadership began as a behavioral health admissions representative

As a Healthcare Regulatory Attorney and former executive, Noreen is a transparent communicator and innovative problem solver with a deep background in operations and risk management.

Noreen’s career in healthcare operations, healthcare compliance and executive leadership began as a behavioral health admissions representative – she understands the day-to-day regulatory hurdles facing healthcare clients. Most recently, Noreen served as Acting CEO, General Counsel and Chief Human Resources Executive for a national managed behavioral health venture with employees across 50 states. In this position, Noreen leveraged her experience in strategic planning, corporate governance, complex contracts, employment law and compliance. Noreen navigated tough decisions including guiding 500 percent growth over 6 years, moving online quickly during COVID-19 and helping secure the largest contract in company history. Earlier in her career, Noreen collaborated in-house at the National Association of Insurance Commissioners (NAIC), where oversight, peer review, best practices and standards are established by state regulators.